Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Validation Study of RA-INF-Dx as a Multigene Molecular Test Intended to Aid in the Identification of Patients With Rheumatoid Arthritis Who Are Unlikely to Show an Initial Response to Infliximab and Methotrexate Combination Therapy

NCT01299545 is registered in ClinicalTrials.gov with TcLand Expression S.A. as lead sponsor.

NCT NCT01299545
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01299545 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Validation Study of RA-INF-Dx as a Multigene Molecular Test Intended to Aid in the Identification of Patients With Rheumatoid Arthritis Who Are Unlikely to Show an Initial Response to Infliximab and Methotrexate Combination Therapy
Lead sponsor
TcLand Expression S.A.
Phase
Observational
Overall status
Terminated
Start date
February 28, 2011
Completion date
October 31, 2012
Enrollment
123 (actual)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis